CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be e...
Phase 3
Kansas City, Missouri, United States and 108 other locations
new drug called ibrutinib in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR) as a possible treatment for Chronic...
Phase 2
Westwood, Kansas, United States and 8 other locations
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...
Phase 2
Kansas City, Missouri, United States and 73 other locations
objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...
Phase 3
Westwood, Kansas, United States and 216 other locations
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study...
Phase 3
Kansas City, Missouri, United States and 59 other locations
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolera...
Phase 1, Phase 2
Kansas City, Kansas, United States and 55 other locations
To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression...
Phase 3
Kansas City, Missouri, United States and 159 other locations
SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory bioma...
Phase 1
Fairway, Kansas, United States and 9 other locations
The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological maligna...
Phase 1, Phase 2
Westwood, Kansas, United States and 19 other locations
This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic...
Phase 1
Westwood, Kansas, United States and 16 other locations
Clinical trials
Research sites
Resources
Legal